

# Evaluation of Left Ventricular Diastolic Dysfunction in diabetic patients with preserved Ejection fraction and its association with myocardial performance index

Bishal Shrestha<sup>1</sup>, Rabi Malla<sup>2</sup>, Arun Maskey<sup>2</sup>, Sujeeb Rajbhandari<sup>2</sup>, Rabindra Simkhada<sup>2</sup>, Arjun Budhathoki<sup>1</sup>, Chitra Raj sharma<sup>1</sup>, Manoj Koirala<sup>1</sup>, Divya Karmacharya<sup>2</sup>, Eloma Shrestha<sup>2</sup>, Sunita Sharma<sup>3</sup>

## Abstract

**Background:** Diastolic dysfunction causes impairment of ventricular filling when the ventricle becomes stiff, relaxes slowly or incompletely. Diabetes mellitus increases the risk of diastolic dysfunction which can develop heart failure even in the absence of other co-morbidities. Tei index is an echocardiographic tool to evaluate global function of ventricle.

**Objective:** To determine the prevalence of Left Ventricular diastolic dysfunction (LVDD) in patients with type 2 diabetes mellitus; and its association with LV myocardial performance index (Tei Index).

**Method:** 100 patients with type 2 diabetes mellitus with normal left ventricular ejection fraction without overt cardiac disease were included. LVDD was determined as per using 2016 American Society of Echocardiology (ASE) guideline. LV Tei index was calculated by tissue doppler imaging method.

**Results:** Mean age of the patients was  $58.1 \pm 12.6$  years with 54 percent male. Mean HbA1C was  $7.45 \pm 0.99$ . 23 (23%) patients met the criteria of LVDD and 46 (46%) patients did not have LVDD. Whereas 31 (31%) of patients were categorized as indeterminate. Tei index was significantly higher in patients with LVDD ( $0.56 \pm 0.05$  and  $0.43 \pm 0.06$  ( $p < 0.05$ )).

**Conclusion:** Prevalence of LV diastolic dysfunction in type 2 diabetes mellitus was 23% in our study. There was a significant association between LVDD and Tei index. Rising trend of prevalence of diastolic dysfunction with increasing age of patients was observed.

**Key Words:** 2016 ASE/EACVI guideline, Diastolic dysfunction, diabetes mellitus, MPI, Tei index, Tissue doppler imaging

J Inv Clin Cardiol 2023; 5(1): 14-18

## Introduction:

Cardiac dysfunction is the major cause of morbidity and mortality in diabetes worldwide<sup>1</sup>. Diabetes is a major risk factor not only for CAD, but also for left ventricular dysfunction and heart failure<sup>2</sup>. In the Framingham Heart Study, it was shown that HF was twice as common among men and five times as common among women with diabetes as among those without diabetes<sup>3</sup>. Diabetic cardiomyopathy is characterized by the development of diastolic dysfunction at the early stage, followed by systolic dysfunction in the absence of coronary artery disease,

hypertension, or significant valvular heart disease<sup>4</sup>. Type 2 diabetes seems to be more strongly associated with the development of HFpEF than with HFrEF. In line with these findings, left ventricular diastolic dysfunction (LVDD), the preclinical stage of HFpEF, is also more prevalent among type 2 diabetes patients than in those without diabetes<sup>5</sup>.

Although type 2 diabetes is a known risk factor of LVDD and HFpEF, the use of echocardiography is in general not considered in existing type 2 diabetes primary care disease management programs.<sup>6</sup> Given the large impact of both diabetes and HFpEF for

1. Department of Cardiology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal

2. Department of Cardiology, Shahid Gangalal National Heart Center, Kathmandu, Nepal

**Address of Correspondence:** Bishal Shrestha, Department of Cardiology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal Email: bishalsth42@yahoo.com

patients and community, it is important to know the exact prevalence of LVDD in patients with type 2 diabetes as this can be helpful to target prevention and intervention strategies for both LVDD and early stages of HFpEF.

American society of echocardiography/European association for cardiovascular imaging ASE/EACVI jointly updated its complex 2009 guideline for detection of LVDD in 2016<sup>7</sup>. The primary goal of this update is to simplify the approach and thus increase the utility of the guidelines in daily clinical practice.

Myocardial Performance Index (MPI/Tei Index), which includes both systolic and diastolic time intervals to assess the global cardiac dysfunction was used by Tei and his co-workers in 1995<sup>8</sup>. The value is independent of Heart Rate and Blood Pressure. It has been evaluated in many cardiac conditions like low heart failure with reduced ejection fraction, Pulmonary Arterial Hypertension, Amyloidosis, Myocardial infarction, congenital heart disease<sup>9</sup>. The cut off value is different among normal and various abnormal cardiac conditions and Higher value of Tei index has been shown to correlate with poor prognosis in symptomatic HF<sup>10</sup>. It has also been used as a surrogate marker for diabetic cardiac dysfunctions in different studies with encouraging results. Tei index can be calculated from pulse wave doppler method and tissue doppler imaging method. Tissue Doppler Imaging (TDI) enables measurement of both relaxation and contraction time simultaneously in single cardiac cycle<sup>11</sup>.

Current study aims to determine the prevalence of LVDD as per updated 2016 ASE/EACVI guideline in our diabetic patients having preserved EF with no evidence of overt cardiac disease and find out the association of LVDD with Tei index.

## Methodology:

This is hospital based, cross sectional, prospective study conducted in Bir Hospital, Kathmandu, Nepal from 2022 February to 2022 August (6 months) with IRB clearance from the institute (NAMS). Diabetic patients with sinus rhythm, normal EF, with no gross structural heart disease (more than mild valvular disease, HCM, DCM, RCM, pericardial disease), without COPD, CKD, no ECG evidence of infarction or bundle branch block were included in the study. Informed consent was taken; Echocardiography was done, recent documents were reviewed and data were collected and recorded as per proforma by the principal investigator.



Following four variables are obtained on echocardiography (phillips affinity) as per ASE/EACVI 2016 guideline to determine whether the patient has LVDD. their abnormal cutoff values are:

- 1) annular e' velocity (septal e' < 7 cm/sec, lateral e' < 10 cm/sec),
- 2) average E/e' ratio > 14,
- 3) LA maximum volume index > 34 mL/m<sup>2</sup> calculated by biplane method and indexed with BSA,
- 4) Peak TR velocity > 2.8 m/sec.

LV diastolic function is considered normal if upto 1 parameter is abnormal. LV diastolic dysfunction is present if at least 3 parameters are abnormal. The study is indeterminate if 2 values are abnormal.

Tei index was calculated from tissue doppler imaging method. The sample volume was placed on septal mitral annulus to get a good TDI signal as shown in figure 1 and schematic graphic representation. The interval "a" is the interval between cessation to onset of diastolic myocardial velocities. The interval "b": the ejection time (ET) is duration of systolic myocardial velocity (SMV). Tei index is calculated from following formula

$$\text{MPI} = (a-b)/b = (\text{IVRT} + \text{IVCT})/\text{ET}.$$



**Data Analysis**

All data were entered into Microsoft Excel and the statistical analysis was done using the SPSS version 26 software (SPSS INC, Chicago, Ill). Categorical variables were analyzed as number and percentage, continuous variable with normal distribution is presented as mean ± SD. After processing of all available information, statistical analysis of their significance was done.

Age, duration of diabetes, and echo parameters were compared between different groups by performing unpaired t-test for normalized data. Categorical variables were compared by chi-square test. Pearson correlation test was used to correlate between MPI and LVDD association. 95% confidence interval was accepted for our study.


**Results**

Total 100 diabetic patients who met the inclusion and exclusion criteria were evaluated. Mean age of the patients was 58.1 ± 12.6 years with 54 percent being male. Mean duration of diabetes was 5.68 ± 5.7 years. and mean HbA1C was 7.45 ± 0.99 (available in 61 patients). (Table 1)


**Table-I**  
*Demographic and Baseline characteristics of study population*

Characteristic.	Mean± SD or. Number (%)
Age(years)	58.14±12.58 years
Male (%)	46 (44.2%)
Duration of Diabetes (years)	5.68±5.7 years
HBA1C	7.45±0.992


Using the criteria of 2016 American society of echocardiography for diagnosis of LVDD, 23 (23%) patients met the criteria of LVDD and 46 (46%) patients did not have LVDD, whereas 31 (31%) of patients were categorized as indeterminate (figure 1). LVDD was more prevalent with advanced age. There was no significant difference in LVDD vs no LVDD as per sex, duration of diabetes and recent HbA1C level. (Figure 2, 3).



**Fig.-1: Prevalence of diastolic dysfunction**



**Fig.-2: Association between age distribution and diastolic dysfunction**




**Fig.-3: Association between sex, duration of diabetes recent HbA1C level and diastolic dysfunction.**

Tei index as calculated from the tissue Doppler imaging was  $0.56 \pm 0.05$  in patients with diastolic dysfunction and  $0.43 \pm 0.06$  in patients with no diastolic dysfunction with significant positive correlation coefficient of 0.695 ( $p = 0.01$ ). (Table 2, figure 4)

**Table-II**  
*Echocardiography parameters noted in patients*  
*Tei index mean  $\pm$  SD*

	Tei index mean $\pm$ SD
LVDD	$0.56 \pm 0.05$
No LVDD	$0.43 \pm 0.058$
Indeterminate	$0.5 \pm 0.053$



**Fig.-4:** comparison of tei index in between the groups

### Discussion:

Prevalence of LVDD is higher in diabetic patients as compared to normal individual<sup>12</sup>. Though inconsistently, studies have shown that older age, higher BMI, longer duration of diabetes, poor glycemic control are associated with increased risk of developing LVDD in diabetes even in the absence of hypertension and coronary artery disease<sup>13,14</sup>. The prevalence of LVDD in asymptomatic diabetic patients varies widely across different studies, ranging from 14% to 71% mainly because of heterogeneity of diagnostic criteria used, populations studied and associated comorbidities<sup>15,16</sup>. A systematic review and meta-analysis done in 2018 found the prevalence to be 46%<sup>17</sup>.

Compared to older 2009 criteria; the updated 2016 ASE criteria detects more advanced and may be more

clinically significant LVDD and is less specific to detect milder form of LVDD. Further studies are warranted to investigate the prognostic impact of these criteria.<sup>18</sup> Validating their accuracy is difficult. One of such attempts was done with multicentric study, where this echocardiographic assessment criteria of LVDD was compared with invasively measured LVEDP; which showed 87% accuracy to diagnose elevated filling pressure of PCWP  $>12$  mmHg<sup>19</sup>.

In a study conducted recently in 200 diabetic and 281 non diabetic, prevalence of LVDD was 17.5% among diabetic and 4.5% among nondiabetic respectively using 2016 ASE criteria to diagnose diastolic dysfunction.<sup>12</sup> These findings demonstrate similar findings of LVDD prevalence as with our study which is significantly lower than other studies which has used older criteria to diagnose LVDD. More number (31%) of study patients in our study have indeterminate study in regard to LVDD assessment which is an inherent issue while using this criterion as also seen in a study by Van de *et al.* which has shown indeterminate study upto 30%<sup>20</sup>.

As systolic and diastolic dysfunction frequently coexist, combined measurement of left ventricular chamber performance such as Tei index was thought to be more reflective. However, it does not determine the cause. The cutoff values have been different in different studies and different conditions. For example, in a study, 'cut off-points' of  $>0.47$  identified patients with mild to moderate heart failure with a sensitivity of 86% and a specificity of 82%<sup>21</sup>. In another study Tei index  $>0.63$  was shown to be good predictor of both LVDP  $>12$  mmHg and LVDD<sup>22</sup>.

One study done in India, which enrolled 100 patients with diabetes without hypertension and overt heart disease. used older criteria (E/A ratio, Valsalva, E/E') to diagnose and categorize LVDD and calculated MPI by PW doppler. Researchers found that 65% had LVDD, Mean Tei index values were significantly higher with increasing diastolic dysfunction (0.24, 0.45, 0.6 and 0.68 among normal, grade 1, grade 2 and grade 3 LVDD)<sup>23</sup>. Lower prevalence of LVDD in our study is because of use of updated guideline to diagnose LVDD. The value of Tei index in patients without LVDD in our study is higher, probably because many of lower grade LVDD in their study population might fall in normal to indeterminate group in our study; and also, the method of measurement of Tei index is different.

### Conclusion:

With updated 2016 guideline 23% of patients had LVDD in patients with diabetes with preserved ejection fraction and without obvious cardiac disease in our study. Increasing age was significantly associated with higher incidence whereas male sex, duration of diabetes and HbA1C level were not significantly different. Tei index was significantly higher in patients with LVDD than those without LVDD.

Limitations of the study : with updated guideline to assess LVDD, significant proportion of patients have indeterminate study and we did not further characterize those subset. furthermore, we have not graded LVDD. We have not taken normal subjects as control group. We have not ruled out subclinical LV systolic dysfunction with abnormal GLS.

**Conflicts of interest:** No conflict

### References

- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract.* 2019;157:107843.
- Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. *Circ Res.* 2019;124(1):121-41.
- Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *Jama.* 1979;241(19):2035-8.
- Grubiæ Rotkviæ P, Planiniæ Z, Liberati Pršo AM, Šikiæ J, Galiaæ E, Rotkviæ L. The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. *Int J Mol Sci.* 2021;22(11).
- Borghetti G, von Lewinski D, Eaton DM, Sourij H, Houser SR, Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. *Beyond Glycemic Control. Front Physiol.* 2018;9:1514.
- Association AD. 1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes—2019. *Diabetes Care.* 2019;42(Supplement\_1):S7-S12.
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2016;29(4):277-314.
- Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function—a study in normals and dilated cardiomyopathy. *J Cardiol.* 1995;26(6):357-66.
- Pellett AA, Tolar WG, Merwin DG, Kerut EK. The Tei index: methodology and disease state values. *Echocardiography.* 2004;21(7):669-72.
- Larina VN, Bart B, Dergunova EN, Alekhin MN. [Prognostic value of the myocardial performance (Tei) index in patients with chronic heart failure]. *Kardiologiya.* 2013;53(11):37-44.
- Abd El Rahman MY, Hui W, Dsebissowa F, Schubert S, Hubler M, Hetzer R, et al. Comparison of the tissue Doppler-derived left ventricular Tei index to that obtained by pulse Doppler in patients with congenital and acquired heart disease. *Pediatr Cardiol.* 2005;26(4):391-5.
- Raghothama S, Rao A. Revelation of subclinical left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus using 2016 ASE/ EACVI guidelines. *Caspian J Intern Med.* 2021;12(4):586-92.
- Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, Pignonblanc PG, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? *J Am Soc Echocardiogr.* 2011;24(11):1268-75.e1.
- Yadava SK, Dolma N, Lamichhane G, Poudel N, Barakoti M, Karki DB. Prevalence of Diastolic Dysfunction in Type 2 Diabetes Mellitus. *Kathmandu Univ Med J (KUMJ).* 2017;15(59):212-6.
- Foo DHP, Lam KH, Igo M, Sulaiman MNAB, Bujang MAB, Ku MY, et al. Impact of 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations for the Evaluation of Left Ventricular Diastolic Function on Predicting Outcomes in Patients with Diabetes and Hypertension without a History. *Journal of Asian Pacific Society of Cardiology* 2022;1:e16. 2022.
- Shrestha NR, Sharma SK, Karki P, Shrestha NK, Acharya P. Echocardiographic evaluation of diastolic function in asymptomatic type 2 diabetes. *JNMA J Nepal Med Assoc.* 2009;48(173):20-3.
- Bouthoorn S, Valstar GB, Gohar A, den Ruijter HM, Reitsma HB, Hoes AW, et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis. *Diab Vasc Dis Res.* 2018;15(6):477-93.
- Grigorescu ED, Lacatusu CM, Floria M, Mihai BM, Cretu I, Sorodoc L. Left Ventricular Diastolic Dysfunction in Type 2 Diabetes-Progress and Perspectives. *Diagnostics (Basel).* 2019;9(3).
- Andersen OS, Smiseth OA, Dokainish H, Abudiyab MM, Schutt RC, Kumar A, et al. Estimating Left Ventricular Filling Pressure by Echocardiography. *J Am Coll Cardiol.* 2017;69(15):1937-48.
- van de Bovenkamp AA, et al. Validation of the 2016 ASE/ EACVI Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction. *J Am Heart Assoc.* 2021;10(18):e021165.
- Bruch C, Schmermund A, Marin D, Katz M, Bartel T, Schaar J, et al. Tei-index in patients with mild-to-moderate congestive heart failure. *Eur Heart J.* 2000;21(22):1888-95.
- Zhang H, Otsuji Y, Matsukida K, Hamasaki S, Yoshifuku S, Kumano-hoso T, et al. Noninvasive differentiation of normal from pseudonormal/restrictive mitral flow using TEI index combining systolic and diastolic function. *Circ J.* 2002;66(9):831-6.
- Goroshi M, Chand D. Myocardial Performance Index (Tei Index): A simple tool to identify cardiac dysfunction in patients with diabetes mellitus. *Indian Heart J.* 2016;68(1):83-7.